- Home
- AXIL vs CMMB Comparison
AXIL vs CMMB Comparison
Compare AXIL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- CMMB
- Stock Information
- Founded
- AXIL 2015
- CMMB 2004
- Country
- AXIL United States
- CMMB Israel
- Employees
- AXIL N/A
- CMMB N/A
- Industry
- AXIL Package Goods/Cosmetics
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- CMMB Health Care
- Exchange
- AXIL Nasdaq
- CMMB Nasdaq
- Market Cap
- AXIL 25.6M
- CMMB 27.0M
- IPO Year
- AXIL N/A
- CMMB N/A
- Fundamental
- Price
- AXIL $4.09
- CMMB $1.65
- Analyst Decision
- AXIL
- CMMB Strong Buy
- Analyst Count
- AXIL 0
- CMMB 3
- Target Price
- AXIL N/A
- CMMB $7.33
- AVG Volume (30 Days)
- AXIL 5.2K
- CMMB 106.7K
- Earning Date
- AXIL 01-09-2025
- CMMB 11-14-2024
- Dividend Yield
- AXIL N/A
- CMMB N/A
- EPS Growth
- AXIL 144.51
- CMMB N/A
- EPS
- AXIL 0.24
- CMMB N/A
- Revenue
- AXIL $27,243,542.00
- CMMB N/A
- Revenue This Year
- AXIL N/A
- CMMB N/A
- Revenue Next Year
- AXIL N/A
- CMMB N/A
- P/E Ratio
- AXIL $17.22
- CMMB N/A
- Revenue Growth
- AXIL 7.30
- CMMB N/A
- 52 Week Low
- AXIL $3.54
- CMMB $0.42
- 52 Week High
- AXIL $14.00
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- AXIL 49.55
- CMMB 55.47
- Support Level
- AXIL $3.54
- CMMB $1.55
- Resistance Level
- AXIL $4.00
- CMMB $1.73
- Average True Range (ATR)
- AXIL 0.30
- CMMB 0.16
- MACD
- AXIL -0.01
- CMMB 0.01
- Stochastic Oscillator
- AXIL 53.16
- CMMB 52.83
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.